secwatch.observer — SEC 8-K summary
======================================

Issuer:     CareDx, Inc. (CDNA)
CIK:        0001217234
Form:       8-K
Filed at:   2026-07-30T20:03:10+00:00
Accession:  0001217234-26-000045
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

CareDx Q2 revenue $132M (+52% YoY); raises FY2026 revenue guidance to $490M-$500M
--------------------------------------------------------------------------------

- Q2 revenue $132M (+52% YoY); Testing Services revenue $100M (+61% YoY) on ~58,000 tests.
- GAAP net income $111M (incl. $113M gain on Lab Products sale) vs loss $9M YoY; non-GAAP EPS $0.37.
- Adjusted EBITDA $25M vs $5M YoY; raised FY2026 revenue guidance to $490M-$500M (from $447M-$465M).
- Raised FY2026 adjusted EBITDA guidance to $66M-$78M (from $43M-$57M).
- Closed Lab Products divestiture to Eurobio Scientific and acquired Naveris; CMS finalized coverage for AlloSure/AlloMap.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1217234/000121723426000045/0001217234-26-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1217234/000121723426000045/cdna-20260730.htm
  HTML page:      https://secwatch.observer/filing/0001217234-26-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer